Explore

Trendline Trendline
Lantern Pharma's LP-300 Shows Promising Results in Lung Cancer Trial, Seeks FDA Guidance

Lantern Pharma's LP-300 Shows Promising Results in Lung Cancer Trial, Seeks FDA Guidance

Lantern Pharma's LP-300 Shows Promising Results in Lung Cancer Trial, Seeks FDA Guidance
Trendline Trendline
Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation

Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation

Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation
Trendline Trendline
NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026

NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026

NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026
Trendline Trendline
Palleon Pharmaceuticals Initiates Clinical Trial for Innovative Cancer Treatment

Palleon Pharmaceuticals Initiates Clinical Trial for Innovative Cancer Treatment

Palleon Pharmaceuticals Initiates Clinical Trial for Innovative Cancer Treatment
Trendline Trendline
EpiBiologics Begins Phase 1 Study of EPI-326 for EGFR-Driven Cancers

EpiBiologics Begins Phase 1 Study of EPI-326 for EGFR-Driven Cancers

EpiBiologics Begins Phase 1 Study of EPI-326 for EGFR-Driven Cancers
Trendline Trendline
FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy

FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy

FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy
Trendline Trendline
Palleon Pharmaceuticals Initiates Clinical Trial for Novel Cancer Therapy Targeting Tumor Hypersialylation

Palleon Pharmaceuticals Initiates Clinical Trial for Novel Cancer Therapy Targeting Tumor Hypersialylation

Palleon Pharmaceuticals Initiates Clinical Trial for Novel Cancer Therapy Targeting Tumor Hypersialylation
Trendline Trendline
Palleon Pharmaceuticals Initiates Clinical Trial for Innovative Cancer Therapy Targeting Immune Evasion

Palleon Pharmaceuticals Initiates Clinical Trial for Innovative Cancer Therapy Targeting Immune Evasion

Palleon Pharmaceuticals Initiates Clinical Trial for Innovative Cancer Therapy Targeting Immune Evasion
Trendline Trendline
Palleon Pharmaceuticals Initiates Clinical Trial for Innovative Cancer Therapy Targeting B7-H3

Palleon Pharmaceuticals Initiates Clinical Trial for Innovative Cancer Therapy Targeting B7-H3

Palleon Pharmaceuticals Initiates Clinical Trial for Innovative Cancer Therapy Targeting B7-H3
Trendline Trendline
Inhibrx to Provide Clinical Update on Ozekibart for Colorectal Cancer

Inhibrx to Provide Clinical Update on Ozekibart for Colorectal Cancer

Inhibrx to Provide Clinical Update on Ozekibart for Colorectal Cancer
Trendline Trendline
FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer

FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer

FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer
Trendline Trendline
Revolution Medicines Reports Promising Results in Pancreatic Cancer Drug Trial

Revolution Medicines Reports Promising Results in Pancreatic Cancer Drug Trial

Revolution Medicines Reports Promising Results in Pancreatic Cancer Drug Trial